Fully Synthetic Vaccines Consisting of Tumor‐Associated MUC1 Glycopeptides and a Lipopeptide Ligand of the Toll‐like Receptor 2

Abstract

Fragment condensation of a protected Pam3Cys lipopeptide with unprotected tumor-associated MUC1 glycopeptides opens the way to vaccine candidates such as A. These vaccines elicit selective immune responses in mice although they lack an immunodominant carrier protein. In principle, such vaccines are applicable to humans. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.